2021

1. Liontos A, Koumpis E, Barkas F, Hatzimichael E, Liamis G, Fever of unknown origin as the only manifestation of multiple myeloma. A case report. Arch Hellen Med, 38(6), November-December 2021, 795-797
2. Voulgari PV, Kapsali E, Leishmaniasis After Multiple Sandfly Bites, J Clin Rheumatol 2021 Sep 1;27(6):e235. doi: 10.1097/RHU.0000000000001374
3. E. Tzavella, L. Gika, E. Hatzimichael, H. Milionis, E. Liberopoulos Severe thrombocytopenia in COVID-19: a case report. Journal of Atherosclerosis Prevention and Treatment, 2021 in press
4. Koumpis E, Tassi I, Malea T, Papathanasiou K, Papakonstantinou I, Serpanou A, Tsolas E, Kapsali E, Vassilakopoulos TP, Papoudou-Bai A, Hatzimichael E, CD56 expression in multiple myeloma: Correlation with poor prognostic markers but no effect on outcome. Pathol Res Pract. 2021 Jul 28;225:153567
5. Papakonstantinou I, Koumpis E, Fytsili E, Panteli A, Milionis H, Papoudou-Bai A, Kapsali E, Hatzimichael E, Leishmaniasis mimicking multiple myeloma. Int J Lab Hematol 2021 Jul 29. doi: 10.1111/ijlh.13667
6. Papakonstantinou I, Kosmidou M, Papathanasiou K, Koumpis E, Kapsali E, Milionis H, Vassilakopoulos TP, Papoudou-Bai A, Hatzimichael E, Paraneoplastic Intrahepatic Cholestasis in Supradiaphragmatic Classical Hodgkin Lymphoma Successfully Treated with Brentuximab Vedotin: A Case Report and Review of the Literature. In Vivo. 2021 Jul-Aug;35(4):1951-1957.
7. Koumpis E, Papathanasiou K, Papakonstantinou I, Tassi I, Serpanou A, Kapsali E, Hatzimichael E, Rifampicin-Induced Thrombocytopenia: A Case Report and Short Review of the Literature. EMJ. 2021; DOI/10.33590/emj/20-00193.
8. Makis A, Voskaridou E, Papassotiriou I, Hatzimichael E. Novel therapeutic advances in β-thalassemia, Biology (Basel) 2021 Jun 18;10(6):546
9. Karakatsanis S; Hellenic Cooperative Lymphoma Group, Papageorgiou SG, Michail M, Angelopoulou MK, Kalpadakis C, Leonidopoulou T, Katodritou E, Kotsopoulou M, Kotsianidis I, Hatzimichael E, Lakiotaki E, Boutsis D, Karianakis G, Symeonidis A, Gavriatopoulou M, Panayiotidis P, Konstantopoulos K, Karmiris T, Pangalis GA, Vassilakopoulos TP. Subdiaphragmatic extranodal localizations at diagnosis of primary mediastinal large B-cell lymphoma: an impressive, rare presentation with no independent effect on prognosis, Leuk Res. 2021 2021 Aug;107:106595. doi: 10.1016/j.leukres.2021.106595. Epub 2021 Apr 24.
10. Liapis K, Papadopoulos V, Vrachiolias G, Galanopoulos AG, Papoutselis M, Papageorgiou SG, Diamantopoulos PT, Pappa V, Viniou NA, Kourakli A, Τsokanas D, Vassilakopoulos TP, Hatzimichael E, Bouronikou E, Ximeri M, Pontikoglou C, Megalakaki A, Zikos P, Panayiotidis P, Dimou M, Karakatsanis S, Papaioannou M, Vardi A, Kontopidou F, Harchalakis N, Adamopoulos I, Symeonidis A, Kotsianidis I. Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes. Blood Cancer J. 2021 Feb 11;11(2):30. doi: 10.1038/s41408-021-00424-4
11. Dimou M, Papageorgiou SG, Stavroyianni N, Katodritou E, Tsirogianni M, Kalpadakis C, Banti A, Arapaki M, Iliakis Th , Bouzani M, Verrou E, Spanoudakis E, Giannouli S, Marinakis Th, Mandala E, Mparmparousi D, Sachanas S, Dalekou-Tsolakou M, Hatzimichael E, Vadikolia Ch, Violaki V, Poziopoulos C,  Tsirkinidis P,  Chatzileontiadou S,  Vervessou E,  Ximeri M,  Sioni A,   Konstantinidou P,   Kyrtsonis M-C, Siakantaris M, Angelopoulou MK, Pappa V,  Konstantopoulos K, Panayiotidis P, Vassilakopoulos TP. Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas. Hematol Oncol 2021 Aug;39(3):336-348.doi: 10.1002/hon.2842. Epub 2021 Mar 2.
12. Vassilakopoulos TP, Michail M, Papageorgiou S, Kourti G, Angelopoulou MK, Panitsas F, Sachanas S, Kalpadakis C, Katodritou E, Leonidopoulou T, Kotsianidis I, Hatzimichael E, Kotsopoulou M, Dimou M, Variamis E, Boutsis D, Terpos E, Dimopoulou MN, Karakatsanis S, Michali E, Karianakis G, Tsirkinidis P, Vadikolia C, Poziopoulos C, Pigaditou A, Vrakidou E, Economopoulos T, Kyriazopoulou L, Siakantaris MP, Kyrtsonis MC, Symeonidis A, Anargyrou K, Papaioannou M, Chatziharissi E, Vervessou E, Tsirogianni M, Palassopoulou M, Gainaru G, Stefanoudaki E, Zikos P, Tsirigotis P, Tsourouflis G, Assimakopoulou T, Konstantinidou P, Papadaki H, Megalakaki K, Dimopoulos MA, Pappa V, Karmiris T, Roussou P, Panayiotidis P, Konstantopoulos K, Pangalis GA. Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP. Oncologist 2021, Jul;26(7):597-609. doi: 10.1002/onco.13789. Epub 2021 Jun 17.
13. Vassilakopoulos TP, Papageorgiou SG, Angelopoulou MK, Chatziioannou S, Prassopoulos V, Karakatsanis S, Arapaki M, Mellios Z, Sachanas S, Kalpadakis C, Katodritou E, Leonidopoulou T, Kotsianidis I, Hatzimichael E, Kotsopoulou M, Dimou M, Variamis E, Boutsis D, Terpos E, Michali E, Karianakis G, Tsirkinidis P, Vadikolia C, Poziopoulos C, Pigaditou A, Vrakidou E, Siakantaris MP, Kyrtsonis MC, Symeonidis A, Anargyrou K, Papaioannou M, Chatziharissi E, Vervessou E, Tsirogianni M, Palassopoulou M, Gainaru G, Mainta C, Tsirigotis P, Assimakopoulou T, Konstantinidou P, Papadaki H, Dimopoulos MA, Pappa V, Karmiris T, Roussou P, Datseris I, Panayiotidis P, Konstantopoulos K, Pangalis GA, Rondogianni P. Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies. Ann Hematol. 2021 Sep;100(9):2279-2292. doi: 10.1007/s00277-021-04421-2. Epub 2021 Feb 1.
14. Vassilakopoulos TP, Piperidou A, Hadjiharissi E, Panteliadou AK, Panitsas F, Vassilopoulos I, Variamis E, Boutsis D, Michail M, Papageorgiou S, Tsourouflis G, Dimou M, Karakatsanis S, Kalpadakis C, Stavroyianni N, Katodritou E, Kotsopoulou M, Kotsianidis I, Verigou E, Hatzimichael E, Leonidopoulou T, Xanthopoulos V, Panayiotidis P, Konstantopoulos K, Dimopoulos MA, Karmiris T, Batsis I, Papaioannou M, Pangalis GA, Angelopoulou MK. Development of Classical Hodgkin Lymphoma after successful treatment of primary mediastinal large b-cell lymphoma: results from a well-defined database. Leuk Res. 2021 Jan;100:106479. doi: 10.1016/j.leukres.2020.106479. Epub 2020 Nov 16.
15. Diamantopoulos PT, Symeonidis A, Pappa V, Kotsianidis I, Galanopoulos A, Pontikoglou C, Anagnostopoulos A, Vassilopoulos G, Zikos P, Hatzimichael E, Papaioannou M, Megalakaki A, Repousis P, Kotsopoulou M, Dimou M, Solomou E, Dryllis G, Tsokanas D, Papoutselis MK, Papageorgiou S, Kyrtshonis MC, Kourakli A, Papadaki H, Panayiotidis P, Viniou NA. The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes. Br J Haematol. 2021 Mar;192(6):978-987. doi: 10.1111/bjh.17062. Epub 2020 Aug 30.
16. Kolios M, Liu T, Vlahos AP, Kapsali E, Korantzopoulos P, Evolution of electrocardiographic abnormalities and arrhythmias in adult patients with beta-thalassemia major during a short-term follow-up, Am J Cardiovasc Dis. 2021 Jun 15;11(3):391-397. eCollection 2021.

1. Papageorgiou S.G,  Kotsianidis I.,  Bouchla A.,  Symeonidis A.,  Galanopoulos A.,  Viniou N-A,  Hatzimichael E.,  Vassilakopoulos T.P,  Gogos D.,  Megalakaki A.,  Zikos P.,  Diamantopoulos P.,  Kourakli A.,  Giannoulia P.,  Papoutselis M.,  Poulakidas E.,  Arapaki M., .Vardi A,  Anagnostopoulos A.,  Mparmparousi D.,  Papaioannou M.,  Bouronikou E.,  Dimou M.,  Papadaki H.,  Panayiotidis P.,  Pappa V. Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes. Ther Adv Hematol. 2020 Dec 8;11:2040620720966121.  doi: 10.1177/2040620720966121. eCollection 2020
2. Pomoni A, Aggeli I, Loutsi E, Hatzimichael E, Chaliasos N, Makis A. Cyanosis Due to Methemoglobinemia as the Presenting Sign of Glucose-6-Phosphate Dehydrogenase Deficiency in a Child: Diagnostic and Clinical Implications. J Pediatr Hematol Oncol. 2020 Oct 7. doi: 10.1097/MPH.0000000000001967.
3. Koumpis E, Florentin M, Hatzimichael E, Liamis G, Hyponatremia in Patients with Hematologic Diseases. J Clin Med 2020 Nov 19;9(11):3721
4. Kosmeri C, Koumpis E, Tsabouri S, Siomou E, Makis A. Hematological manifestations of SARS-CoV-2 in children, Pediatr Blood Cancer. 2020 Dec;67(12):e28745. doi: 10.1002/pbc.28745. Epub 2020 Oct 3.
5. Mavroeidis L, Vassou A, Zarkavelis G, Papadaki A, Mouzaki I, Ntellas P, Gkoura S, Gazouli I, Pentheroudakis G., Acquired Hemophilia in an Elderly Patient with Carcinoma of the Ampulla of Vater, Case Rep Oncol. 2020 Jan 13;13(1):1-6. doi: 10.1159/000504338. eCollection Jan-Apr 2020.
6. Papadopoulos V, Diamantopoulos PT, Papageorgiou SG, Papoutselis M, Vrachiolias G, Pappa V, Galanopoulos AG, Vassilakopoulos TP, Hatzimichael E, Zikos P, Papadak HA, Bouchla A, Panayiotidis P, Megalakaki A, Papaioannou M, Liapis K.  Dryllis G, Τsokanas D, Kourakli A, Symeonidis, A Viniou NA, Kotsianidis I. Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic Syndromes. Hematological Oncology 2020 Oct;38(4):541-553. doi: 10.1002/hon.2756. Epub 2020 Jun 26
7. Diamantopoulos PT, Pappa V, Symeonidis A, Kotsianidis I, Galanopoulos A, Papadaki H, Anagnostopoulos A, Vassilopoulos G, Zikos P, Hatzimichael E, Papaioannou M, Megalakaki A, Kotsopoulou M, Repousis P, Dimou M, Solomou E, Pontikoglou C, Kyriakakis G, Tsokanas D, Papoutselis MK, Papageorgiou S, Kourakli A, Panayiotidis P, Viniou NA. Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine Registry. Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):114-121.
8. Papageorgiou SG, Kontos CK, Kotsianidis I, Karousi P, Symeonidis A, Galanopoulos A, Bouchla A, Hatzimichael E, Repousis P, Zikos P, Viniou NA, Poulakidas E, Vassilakopoulos TP, Diamantopoulos P, Mparmparousi D, Bouronikou E, Papadaki H, Panayiotidis P, Pappa V. Effectiveness of 5-Azacytidine in older patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia: A retrospective analysis of the Hellenic (Greek) MDS Study Group. J Geriatr Oncol. 2020 Jan;11(1):121-124

2019

1. Diamantopoulos P, Koumbi D, Kotsianidis I, Pappa V, Symeonidis A, Galanopoulos A, Zikos P, Papadaki HA, Panayiotidis P, Dimou M, Hatzimichael E, Vassilopoulos G, Delimpasis S, Mparmparousi D, Papageorgiou S, Variami E, Kyrtsonis MC, Megalakaki A, Kotsopoulou M, Repousis P, Adamopoulos I, Kontopidou F, Christoulas D, Kourakli A, Tsokanas D, Konstantinos Papoutselis M, Kyriakakis G, Viniou NA; Hellenic MDS study group. The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registry. Cancer Med. 2019 May;8(5):2056-2063.
2. Makis A, Georgiou I, Traeger-Synodinos J, Storino MR, Giuliano M, Andolfo I, Hatzimichael E, Chaliasos N, Giapros V, Izzo P, Iolascon A, Grosso M. A Novel εγδβ-Thalassemia Deletion Associated with Severe Anemia at Birth and a β-Thalassemia Intermedia Phenotype Later in Life in Three Generations of a Greek Family. Hemoglobin. 2019 Dec 12:1-4.
3. Papoudou-Bai A, Vassou A, Marinos L, Papathanasiou K, Kapsali E, Kanavaros P, Concurrent cutaneous localization of Langerhans cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma in a patient with a history of chronic lymphocytic leukemia/small lymphocytic lymphoma, J Cutan Pathol. 2020 Feb;47(2):161-165.doi: 10.1111/cup.13571. Epub 2019 Aug 23
4. Papoudou-Bai A, Marinos L, Vassou A, Kapsali E, Kanavaros P, CD5-Positive Primary Cutaneous Diffuse Large B-Cell Lymphoma-Leg Type, Case Rep Dermatol Med. 2019 Jan 16;2019:3730915. doi: 10.1155/2019/3730915. eCollection 2019
5. Kastritis E, Morel P, Duhamel A, Gavriatopoulou M, Kyrtsonis MC, Durot E, Symeonidis A, Laribi K, Hatjiharissi E, Ysebaert L, Vassou A, Giannakoulas N, Merlini G, Repousis P, Varettoni M, Michalis E, Hivert B, Michail M, Katodritou E, Terpos E, Leblond V, Dimopoulos MA, A revised international prognostic score system for Waldenström’s macroglobulinemia, Leukemia. 2019 Nov;33(11):2654-2661doi: 10.1038/s41375-019-0431-y. Epub 2019 May 22

2018

1. Papoudou-Bai A, Marinos L, Papathanasiou K, Kanavaros P, Kapsali E, Simultaneous Presence of Follicular Lymphoma, Diffuse Large B-cell Lymphoma, and Hodgkin-like Lymphoma, Turk J Haematol. 2018 Nov 13;35(4):308-309. doi: 10.4274/tjh.2018.0183. Epub 2018 Aug 1.
2. Gaitanis G, Gougopoulou D, Kapsali E, Bassukas ID, Sustained Regression of Hydroxycarbamide Induced Actinic Keratoses after Switching to Anagrelide, Case Rep Dermatol Med. 2018 Mar 27;2018:2874012. doi: 10.1155/2018/2874012. eCollection 2018
3. Mauri D, Zarkavelis G, Filis P, Tsali L, Zafeiri G, Papadaki A, Vassou A, Georgopoulos C, Pentheroudakis G, Postoperative chemotherapy with single-agent fluoropyrimidines after resection of colorectal cancer liver metastases: a meta-analysis of randomised trials, ESMO Open. 2018 Jun 23;3(4):e000343. doi: 10.1136/esmoopen-2018-000343. eCollection 2018.
4. Boussios S, Zerdes I, Vassou A, Bareta E, Seraj E, Papoudou-Bai A, Pavlidis N, Batistatou A, Pentheroudakis G, Extranodal diffuse large B-cell lymphomas: A retrospective case series and review of the literature, Hematol Rep. 2018 Apr 3;10(1):7070.doi: 10.4081/hr.2018.7070. eCollection 2018 Mar 2
5. Tsolkas G, Komninou D, Briasoulis E, Hatzimichael E, Papanikolaou NA. A Novel Therapeutic Approach in Acute Promyelocytic Leukemia with All-trans retinoic Acid and Cyclin-dependent Kinase Inhibitors. Clin Cancer Drugs 2018;5: 50-59
6. Diamantopoulos PT, Kotsianidis I, Symeonidis A, Pappa V, Galanopoulos A, Gogos D, Karakatsanis S, Papadaki H, Palla A, Hatzimichael E, Dimou M, Papageorgiou S, Delimpasis S, Papaioannou M, Papoutselis M, Kourakli A, Tsokanas D, Anagnostopoulos A, Kontos CK, Panayiotidis P, Viniou NA; Hellenic MDS study group. Chronic myelomonocytic leukemia treated with 5-azacytidine – results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system. Leuk Lymphoma. Leuk Lymphoma. 2019 Jul;60(7):1721-1730. doi: 10.1080/10428194.2018.1540783. Epub 2018 Nov 14
7. Papageorgiou SG, Kontos CK, Kotsianidis I, Vasilatou D, Symeonidis A, Galanopoulos A, Bouchla A, Hatzimichael E, Repousis P, Zikos P, Viniou NA, Poulakidas E, Vassilakopoulos TP, Diamantopoulos P, Diamantopoulos MA, Mparmparousi D, Bouronikou E, Papadaki H, Panayiotidis P, Pappa V. The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group. Hematol Oncol.  2018 Oct;36(4):693-700
8. Papageorgiou SG, Kotsianidis I, Kontos CK, Symeonidis A, Galanopoulos A, Hatzimichael E, Poulakidas E, Diamantopoulos P, Vassilakopoulos TP, Zikos P, Papadaki H, Bouronikou E, Panayiotidis P, Viniou NA, Pappa V. Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group. Leuk Res. 2018 Jul 7;71:55-59. doi: 10.1016/j.leukres.2018.07.004.
9. Katodritou E, Kyrtsonis MC, Delimpasi S, Kyriakou D, Symeonidis A, Spanoudakis E, Vasilopoulos G, Anagnostopoulos A, Kioumi A, Zikos P, Aktypi A, Briasoulis E, Megalakaki A, Repousis P, Adamopoulos I, Gogos D, Kotsopoulou M, Pappa V, Papadaki E, Fotiou D, Nikolaou E, Giannopoulou E, Hatzimichael E, Giannakoulas N, Douka V, Kokoviadou K, Timotheatou D, Terpos E. Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival. Ann Hematol. 2018 Sep;97(9):1671-1682. doi: 10.1007/s00277-018-3361-2. Epub 2018 May 13.
10. Tsirigotis P, Vassilakopoulos T, Batsis I, Bousiou Z, Gkirkas K, Sakellari I, Kaloyannidis P, Roussou P, Pangalis GA, Moschogiannis M, Vassilopoulos G, Repousis P, Megalakaki A, Michalis E, Kalpadakis C, Papadaki HA, Kotsianidis I, Hatzimichael E, Spyridonidis A, Anargyrou K, Poulakidas E, Giannoullia P, Apostolidis I, Stamouli M, Konstantopoulos K, Pappa V, Panayiotidis P, Harhalakis N, Anagnostopoulos A, Angelopoulou M. Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis. Hematol Oncol. 2018 Jun 8. doi: 10.1002/hon.2521.
11. Papageorgiou SG, Vasilatou D, Kontos CK, Kotsianidis I, Symeonidis A, Galanopoulos AG, Hatzimichael E, Megalakaki A, Poulakidas E, Diamantopoulos P, Vassilakopoulos TP, Zikos P, Papadaki H, Mparmparousi D, Bouronikou E, Panayiotidis P, Viniou NA, Pappa V. The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group. Am J Hematol. 2018 Jul;93(7):895-901. doi: 10.1002/ajh.25111. Epub 2018 May 16.
12. Angelopoulou MK, Vassilakopoulos TP, Batsis I, Sakellari I, Gkirkas K, Pappa V, Giannoulia P, Apostolidis I, Apostolopoulos C, Roussou P, Panayiotidis P, Dimou M, Kyrtsonis MC, Palassopoulou M, Vassilopoulos G, Moschogiannis M, Kalpadakis C, Margaritis D, Spyridonidis A, Michalis E, Anargyrou K, Repousis P, Hatzimichael E, Bousiou Z, Poulakidas E, Grentzelias D, Harhalakis N, Pangalis GA, Anagnostopoulos A, Tsirigotis P. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience. Hematol Oncol. 2018 Feb;36(1):174-181.doi: 10.1002/hon.2383.

2017

1. Biziota E, Mavroiedis L, Hatzimichael E, Pappas P. Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation. Cancer Lett 2017 Aug 1;400:243-251. doi: 10.1016/j.canlet.2016.12.018.
2. Makis A, Gkoutsias A, Palianopoulos T, Pappa E, Papapetrou E, Tsaousi C, Hatzimichael E, Chaliasos N. Prognostic Factors for Immune Thrombocytopenia Outcome in Greek Children: A Retrospective Single-Centered Analysis. Adv Hematol. 2017 2017;2017:7878605. doi: 10.1155/2017/7878605. Epub 2017 Dec 6.
3. Zagouri F, Kastritis E, Zomas A, Terpos E, Katodritou E, Symeonidis A, Delimpasi S, Pouli A, Vassilakopoulos TP, Michalis E, Giannouli S, Kartasis Z, Christoforidou A, Kokoviadou K, Hatzimichael E, Gika D, Megalakaki C, Papaioannou M, Kyrtsonis MC, Konstantopoulos K, Dimopoulos MA; Greek Myeloma Study Group. Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. Eur J Haematol. 2017 Nov;99(5):409-414. doi: 10.1111/ejh.12923. Epub 2017 Sep 26.PMID: 2867576
4. Tzavella E, Hatzimichael E, Kostara C, Bairaktari E, Elisaf M, Tsimihodimos V. Sitosterolemia: A multifaceted metabolic disorder with important clinical consequences. J Clin Lipidol. Jul-Aug;11(4):1095-1100. doi: 10.1016/j.jacl.2017.04.116. Epub 2017 Apr 30
5. Lambri E, Sainis I, Kounnis I, Mistelou A, Ioachim E, Hatzimichael E, Galani V, Briasoulis E. SLCO1B3 screening in colorectal cancer patients using High-Resolution Melting Analysis method and immunohistochemistry. Tumour Biol. 2017 Mar;39(3)
6. Hatzimichael E, Papathanasiou K, Zerdes I, Flindris S, Papoudou-Bai A, Kapsali E., Plasmablastic Lymphoma with Coexistence of Chronic Lymphocytic Leukemia in an Immunocompetent Patient: A Case Report and Mini-Review, Case Rep Hematol. 2017;2017:2861596. doi: 10.1155/2017/2861596. Epub 2017 Nov 20.
7. Apostolou C, Klonizakis P, Mainou M, Kapsali E, Kafantari K, Kotsiafti A, Vetsiou E, Vakalopoulou S, Vlachaki E., Rivaroxaban Use in Patients with Hemoglobinopathies, Hemoglobin. 2017 May;41(3):223-224. doi: 10.1080/03630269.2017.1374969
8. Kastrisiou M, Kostadima FL, Kefas A, Zarkavelis G, Kapodistrias N, Ntouvelis E, Petrakis D, Papadaki A, Vassou A, Pentheroudakis G., Nivolumab-induced hypothyroidism and selective pituitary insufficiency in a patient with lung adenocarcinoma: a case report and review of the literature, ESMO Open. 2017 Oct 5;2(4):e000217. doi: 10.1136/esmoopen-2017-000217. eCollection 2017.
9. Papoudou-Bai A, Hatzimichael E, Barbouti A, Kanavaros P.  Expression patterns of the activator protein-1 (AP-1) family members in lymphoid neoplasms. Clin Exp Med. 2017Aug;17(3):291-304.

2016

1. Hatzimichael E, Briasoulis E. Megaloblastic anemia presenting with skin hyperpigmentation. International Journal of Hematology, 2016; 103(5):479-80
2. Makis A, Hatzimichael E, Papassotiriou I, Voskaridou E. 2017 Clinical trials update in new treatments of β-thalassemia. Am J Hematol 2016 Nov;91(11):1135-1145
3. Kolios M, Korantzopoulos P, Vlahos AP, Kapsali E, Briasoulis E, Goudevenos JA., Electrocardiographic abnormalities and arrhythmic risk markers in adult patients with beta thalassemia major, Int J Cardiol. 2016 Oct 15;221:932-6. doi: 10.1016/j.ijcard.2016.07.037. Epub 2016 Jul 5
4. Papoudou-Bai A, Vassou A, Vartholomatos G, Briasoulis E, Kanavaros P,  Composite hairy cell leukemia and chronic lymphocytic leukemia, J BUON. Jul-Aug 2016;21(4):1027-1029.
5. Hatzimichael E, Lagos K, Vassou A, Gougopoulou D, Papoudou-Bai A, Briasoulis E, Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatment, Mol Clin Oncol. 2016 Jul;5(1):23-26. doi: 10.3892/mco.2016.866. Epub 2016 Apr 20
6. Vassilakopoulos TP, Pangalis GA, Chatziioannou S, Papageorgiou S, Angelopoulou MK, Galani Z, Kourti G, Prassopoulos V, Leonidopoulou T, Terpos E, Dimopoulou MN, Sachanas S, Kalpadakis C, Konstantinidou P, Boutsis D, Stefanoudaki E, Kyriazopoulou L, Siakantaris MP, Kyrtsonis MC, Variami E, Kotsianidis I, Symeonidis A, Michali E, Katodritou E, Kokkini G, Tsatalas C, Papadaki H, Dimopoulos MA, Sotiropoulos V, Pappa V, Karmiris T, Meletis J, Apostolidis J, Datseris I, Panayiotidis P, Konstantopoulos K, Roussou P, Rondogianni P. PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy, Leukemia. 2016 Jan;30(1):238-42. doi: 10.1038/leu.2015.120. Epub 2015 May 14.

1. Karakatsanis S; Hellenic Cooperative Lymphoma Group, Papageorgiou SG, Michail M, Angelopoulou MK, Kalpadakis C, Leonidopoulou T, Katodritou E, Kotsopoulou M, Kotsianidis I, Hatzimichael E, Lakiotaki E, Boutsis D, Karianakis G, Symeonidis A, Gavriatopoulou M, Panayiotidis P, Konstantopoulos K, Karmiris T, Pangalis GA, Vassilakopoulos TP. Subdiaphragmatic extranodal localizations at diagnosis of primary mediastinal large B-cell lymphoma: an impressive, rare presentation with no independent effect on prognosis, Leuk Res. 2021 2021 Aug;107:106595. doi: 10.1016/j.leukres.2021.106595. Epub 2021 Apr 24. 

2. Diamantopoulos PT, Symeonidis A, Pappa V, Kotsianidis I, Galanopoulos A, Pontikoglou C, Anagnostopoulos A, Vassilopoulos G, Zikos P, Hatzimichael E, Papaioannou M, Megalakaki A, Repousis P, Kotsopoulou M, Dimou M, Solomou E, Dryllis G, Tsokanas D, Papoutselis MK, Papageorgiou S, Kyrtshonis MC, Kourakli A, Papadaki H, Panayiotidis P, Viniou NA. The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes. Br J Haematol. 2021 Mar;192(6):978-987. doi: 10.1111/bjh.17062. Epub 2020 Aug 30.

3. Liapis K, Papadopoulos V, Vrachiolias G, Galanopoulos AG, Papoutselis M, Papageorgiou SG, Diamantopoulos PT, Pappa V, Viniou NA, Kourakli A, Τsokanas D, Vassilakopoulos TP, Hatzimichael E, Bouronikou E, Ximeri M, Pontikoglou C, Megalakaki A, Zikos P, Panayiotidis P, Dimou M, Karakatsanis S, Papaioannou M, Vardi A, Kontopidou F, Harchalakis N, Adamopoulos I, Symeonidis A, Kotsianidis I. Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes. Blood Cancer J. 2021 Feb 11;11(2):30. doi: 10.1038/s41408-021-00424-4

4. Dimou M, Papageorgiou SG, Stavroyianni N, Katodritou E, Tsirogianni M, Kalpadakis C, Banti A, Arapaki M, Iliakis Th , Bouzani M, Verrou E, Spanoudakis E, Giannouli S, Marinakis Th, Mandala E, Mparmparousi D, Sachanas S, Dalekou-Tsolakou M, Hatzimichael E, Vadikolia Ch, Violaki V, Poziopoulos C,  Tsirkinidis P,  Chatzileontiadou S,  Vervessou E,  Ximeri M,  Sioni A,   Konstantinidou P,   Kyrtsonis M-C, Siakantaris M, Angelopoulou MK, Pappa V,  Konstantopoulos K, Panayiotidis P, Vassilakopoulos TP. Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas. Hematol Oncol 2021 Aug;39(3):336-348.doi: 10.1002/hon.2842. Epub 2021 Mar 2.

5. Vassilakopoulos TP, Michail M, Papageorgiou S, Kourti G, Angelopoulou MK, Panitsas F, Sachanas S, Kalpadakis C, Katodritou E, Leonidopoulou T, Kotsianidis I, Hatzimichael E, Kotsopoulou M, Dimou M, Variamis E, Boutsis D, Terpos E, Dimopoulou MN, Karakatsanis S, Michali E, Karianakis G, Tsirkinidis P, Vadikolia C, Poziopoulos C, Pigaditou A, Vrakidou E, Economopoulos T, Kyriazopoulou L, Siakantaris MP, Kyrtsonis MC, Symeonidis A, Anargyrou K, Papaioannou M, Chatziharissi E, Vervessou E, Tsirogianni M, Palassopoulou M, Gainaru G, Stefanoudaki E, Zikos P, Tsirigotis P, Tsourouflis G, Assimakopoulou T, Konstantinidou P, Papadaki H, Megalakaki K, Dimopoulos MA, Pappa V, Karmiris T, Roussou P, Panayiotidis P, Konstantopoulos K, Pangalis GA. Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP. Oncologist 2021, Jul;26(7):597-609. doi: 10.1002/onco.13789. Epub 2021 Jun 17.

6. Vassilakopoulos TP, Papageorgiou SG, Angelopoulou MK, Chatziioannou S, Prassopoulos V, Karakatsanis S, Arapaki M, Mellios Z, Sachanas S, Kalpadakis C, Katodritou E, Leonidopoulou T, Kotsianidis I, Hatzimichael E, Kotsopoulou M, Dimou M, Variamis E, Boutsis D, Terpos E, Michali E, Karianakis G, Tsirkinidis P, Vadikolia C, Poziopoulos C, Pigaditou A, Vrakidou E, Siakantaris MP, Kyrtsonis MC, Symeonidis A, Anargyrou K, Papaioannou M, Chatziharissi E, Vervessou E, Tsirogianni M, Palassopoulou M, Gainaru G, Mainta C, Tsirigotis P, Assimakopoulou T, Konstantinidou P, Papadaki H, Dimopoulos MA, Pappa V, Karmiris T, Roussou P, Datseris I, Panayiotidis P, Konstantopoulos K, Pangalis GA, Rondogianni P. Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies. Ann Hematol. 2021 Sep;100(9):2279-2292. doi: 10.1007/s00277-021-04421-2. Epub 2021 Feb 1.

7. Papageorgiou S.G,  Kotsianidis I.,  Bouchla A.,  Symeonidis A.,  Galanopoulos A.,  Viniou N-A,  Hatzimichael E.,  Vassilakopoulos T.P,  Gogos D.,  Megalakaki A.,  Zikos P.,  Diamantopoulos P.,  Kourakli A.,  Giannoulia P.,  Papoutselis M.,  Poulakidas E.,  Arapaki M., .Vardi A,  Anagnostopoulos A.,  Mparmparousi D.,  Papaioannou M.,  Bouronikou E.,  Dimou M.,  Papadaki H.,  Panayiotidis P.,  Pappa V. Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes. Ther Adv Hematol. 2020 Dec 8;11:2040620720966121.  doi: 10.1177/2040620720966121. eCollection 2020

8. Papageorgiou SG, Kontos CK, Kotsianidis I, Karousi P, Symeonidis A, Galanopoulos A, Bouchla A, Hatzimichael E, Repousis P, Zikos P, Viniou NA, Poulakidas E, Vassilakopoulos TP, Diamantopoulos P, Mparmparousi D, Bouronikou E, Papadaki H, Panayiotidis P, Pappa V. Effectiveness of 5-Azacytidine in older patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia: A retrospective analysis of the Hellenic (Greek) MDS Study Group. J Geriatr Oncol. 2020 Jan;11(1):121-124

9. Vassilakopoulos TP, Piperidou A, Hadjiharissi E, Panteliadou AK, Panitsas F, Vassilopoulos I, Variamis E, Boutsis D, Michail M, Papageorgiou S, Tsourouflis G, Dimou M, Karakatsanis S, Kalpadakis C, Stavroyianni N, Katodritou E, Kotsopoulou M, Kotsianidis I, Verigou E, Hatzimichael E, Leonidopoulou T, Xanthopoulos V, Panayiotidis P, Konstantopoulos K, Dimopoulos MA, Karmiris T, Batsis I, Papaioannou M, Pangalis GA, Angelopoulou MK. Development of Classic Hodgkin Lymphoma after successful treatment of primary mediastinal large b-cell lymphoma: results from a well-defined database. Leuk Res. 2021 Jan;100:106479. doi: 10.1016/j.leukres.2020.106479. Epub 2020 Nov 16.

10. Kolios M, Liu T, Vlahos AP, Kapsali E, Korantzopoulos P, Evolution of electrocardiographic abnormalities and arrhythmias in adult patients with beta-thalassemia major during a short-term follow-up, Am J Cardiovasc Dis. 2021 Jun 15;11(3):391-397. eCollection 2021.

11. Papadopoulos V, Diamantopoulos PT, Papageorgiou SG, Papoutselis M, Vrachiolias G, Pappa V, Galanopoulos AG, Vassilakopoulos TP, Hatzimichael E, Zikos P, Papadak HA, Bouchla A, Panayiotidis P, Megalakaki A, Papaioannou M, Liapis K.  Dryllis G, Τsokanas D, Kourakli A, Symeonidis, A Viniou NA, Kotsianidis I. Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic Syndromes. Hematological Oncology 2020 Oct;38(4):541-553. doi: 10.1002/hon.2756. Epub 2020 Jun 26

12. Diamantopoulos PT, Pappa V, Symeonidis A, Kotsianidis I, Galanopoulos A, Papadaki H, Anagnostopoulos A, Vassilopoulos G, Zikos P, Hatzimichael E, Papaioannou M, Megalakaki A, Kotsopoulou M, Repousis P, Dimou M, Solomou E, Pontikoglou C, Kyriakakis G, Tsokanas D, Papoutselis MK, Papageorgiou S, Kourakli A, Panayiotidis P, Viniou NA. Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine Registry. Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):114-121.

13. Kastritis E, Morel P, Duhamel A, Gavriatopoulou M, Kyrtsonis MC, Durot E, Symeonidis A, Laribi K, Hatjiharissi E, Ysebaert L, Vassou A, Giannakoulas N, Merlini G, Repousis P, Varettoni M, Michalis E, Hivert B, Michail M, Katodritou E, Terpos E, Leblond V, Dimopoulos MA, A revised international prognostic score system for Waldenström’s macroglobulinemia, Leukemia. 2019 Nov;33(11):2654-2661doi: 10.1038/s41375-019-0431-y. Epub 2019 May 22

14. Diamantopoulos P, Koumbi D, Kotsianidis I, Pappa V, Symeonidis A, Galanopoulos A, Zikos P, Papadaki HA, Panayiotidis P, Dimou M, Hatzimichael E, Vassilopoulos G, Delimpasis S, Mparmparousi D, Papageorgiou S, Variami E, Kyrtsonis MC, Megalakaki A, Kotsopoulou M, Repousis P, Adamopoulos I, Kontopidou F, Christoulas D, Kourakli A, Tsokanas D, Konstantinos Papoutselis M, Kyriakakis G, Viniou NA; Hellenic MDS study group. The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registry. Cancer Med. 2019 May;8(5):2056-2063.

15. Diamantopoulos PT, Kotsianidis I, Symeonidis A, Pappa V, Galanopoulos A, Gogos D, Karakatsanis S, Papadaki H, Palla A, Hatzimichael E, Dimou M, Papageorgiou S, Delimpasis S, Papaioannou M, Papoutselis M, Kourakli A, Tsokanas D, Anagnostopoulos A, Kontos CK, Panayiotidis P, Viniou NA; Hellenic MDS study group. Chronic myelomonocytic leukemia treated with 5-azacytidine – results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system. Leuk Lymphoma. Leuk Lymphoma. 2019 Jul;60(7):1721-1730. doi: 10.1080/10428194.2018.1540783. Epub 2018 Nov 14

16. Papageorgiou SG, Kontos CK, Kotsianidis I, Vasilatou D, Symeonidis A, Galanopoulos A, Bouchla A, Hatzimichael E, Repousis P, Zikos P, Viniou NA, Poulakidas E, Vassilakopoulos TP, Diamantopoulos P, Diamantopoulos MA, Mparmparousi D, Bouronikou E, Papadaki H, Panayiotidis P, Pappa V. The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group. Hematol Oncol.  2018 Oct;36(4):693-700

17. Papageorgiou SG, Kotsianidis I, Kontos CK, Symeonidis A, Galanopoulos A, Hatzimichael E, Poulakidas E, Diamantopoulos P, Vassilakopoulos TP, Zikos P, Papadaki H, Bouronikou E, Panayiotidis P, Viniou NA, Pappa V. Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group. Leuk Res. 2018 Jul 7;71:55-59. doi: 10.1016/j.leukres.2018.07.004.

18. Katodritou E, Kyrtsonis MC, Delimpasi S, Kyriakou D, Symeonidis A, Spanoudakis E, Vasilopoulos G, Anagnostopoulos A, Kioumi A, Zikos P, Aktypi A, Briasoulis E, Megalakaki A, Repousis P, Adamopoulos I, Gogos D, Kotsopoulou M, Pappa V, Papadaki E, Fotiou D, Nikolaou E, Giannopoulou E, Hatzimichael E, Giannakoulas N, Douka V, Kokoviadou K, Timotheatou D, Terpos E. Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival. Ann Hematol. 2018 Sep;97(9):1671-1682. doi: 10.1007/s00277-018-3361-2. Epub 2018 May 13.

19. Tsirigotis P, Vassilakopoulos T, Batsis I, Bousiou Z, Gkirkas K, Sakellari I, Kaloyannidis P, Roussou P, Pangalis GA, Moschogiannis M, Vassilopoulos G, Repousis P, Megalakaki A, Michalis E, Kalpadakis C, Papadaki HA, Kotsianidis I, Hatzimichael E, Spyridonidis A, Anargyrou K, Poulakidas E, Giannoullia P, Apostolidis I, Stamouli M, Konstantopoulos K, Pappa V, Panayiotidis P, Harhalakis N, Anagnostopoulos A, Angelopoulou M. Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis. Hematol Oncol. 2018 Jun 8. doi: 10.1002/hon.2521.

20. Papageorgiou SG, Vasilatou D, Kontos CK, Kotsianidis I, Symeonidis A, Galanopoulos AG, Hatzimichael E, Megalakaki A, Poulakidas E, Diamantopoulos P, Vassilakopoulos TP, Zikos P, Papadaki H, Mparmparousi D, Bouronikou E, Panayiotidis P, Viniou NA, Pappa V. The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group. Am J Hematol. 2018 Jul;93(7):895-901. doi: 10.1002/ajh.25111. Epub 2018 May 16.

21. Makis A, Gkoutsias A, Palianopoulos T, Pappa E, Papapetrou E, Tsaousi C, Hatzimichael E, Chaliasos N. Prognostic Factors for Immune Thrombocytopenia Outcome in Greek Children: A Retrospective Single-Centered Analysis. Adv Hematol. 2017 2017;2017:7878605. doi: 10.1155/2017/7878605. Epub 2017 Dec 6.

22. Zagouri F, Kastritis E, Zomas A, Terpos E, Katodritou E, Symeonidis A, Delimpasi S, Pouli A, Vassilakopoulos TP, Michalis E, Giannouli S, Kartasis Z, Christoforidou A, Kokoviadou K, Hatzimichael E, Gika D, Megalakaki C, Papaioannou M, Kyrtsonis MC, Konstantopoulos K, Dimopoulos MA; Greek Myeloma Study Group. Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. Eur J Haematol. 2017 Nov;99(5):409-414. doi: 10.1111/ejh.12923. Epub 2017 Sep 26.PMID: 2867576

     

     

23. Angelopoulou MK, Vassilakopoulos TP, Batsis I, Sakellari I, Gkirkas K, Pappa V, Giannoulia P, Apostolidis I, Apostolopoulos C, Roussou P, Panayiotidis P, Dimou M, Kyrtsonis MC, Palassopoulou M, Vassilopoulos G, Moschogiannis M, Kalpadakis C, Margaritis D, Spyridonidis A, Michalis E, Anargyrou K, Repousis P, Hatzimichael E, Bousiou Z, Poulakidas E, Grentzelias D, Harhalakis N, Pangalis GA, Anagnostopoulos A, Tsirigotis P. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience. Hematol Oncol. 2018 Feb;36(1):174-181.doi: 10.1002/hon.2383.

24. Kolios M, Korantzopoulos P, Vlahos AP, Kapsali E, Briasoulis E, Goudevenos JA., Electrocardiographic abnormalities and arrhythmic risk markers in adult patients with beta thalassemia major, Int J Cardiol. 2016 Oct 15;221:932-6. doi: 10.1016/j.ijcard.2016.07.037. Epub 2016 Jul 5

25. Papadopoulou V, Kontandreopoulou E, Panayiotidis P, Roumelioti M, Angelopoulou M, Kyriazopoulou L, Diamantopoulos PT, Vaiopoulos G, Variami E, Kotsianidis I, Athina Viniou N. Expression, prognostic significance and mutational analysis of protein tyrosine phosphatase SHP-1 in chronic myeloid leukemia, Leuk Lymphoma. 2016 May;57(5):1182-8. doi: 10.3109/10428194.2015.1090573. Epub 2015 Dec 23.,

26. Vassilakopoulos TP, Pangalis GA, Chatziioannou S, Papageorgiou S, Angelopoulou MK, Galani Z, Kourti G, Prassopoulos V, Leonidopoulou T, Terpos E, Dimopoulou MN, Sachanas S, Kalpadakis C, Konstantinidou P, Boutsis D, Stefanoudaki E, Kyriazopoulou L, Siakantaris MP, Kyrtsonis MC, Variami E, Kotsianidis I, Symeonidis A, Michali E, Katodritou E, Kokkini G, Tsatalas C, Papadaki H, Dimopoulos MA, Sotiropoulos V, Pappa V, Karmiris T, Meletis J, Apostolidis J, Datseris I, Panayiotidis P, Konstantopoulos K, Roussou P, Rondogianni P. PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy, Leukemia. 2016 Jan;30(1):238-42. doi: 10.1038/leu.2015.120. Epub 2015 May 14.

27. Kastritis E, Gavriatopoulou M, Kyrtsonis MC, Roussou M, Hadjiharissi E, Symeonidis A, Repoussis P, Michalis E, Delimpasi S, Tsatalas K, Tsirigotis P, Vassou A, Vervessou E, Katodritou E, Gika D, Terpos E, Dimopoulos MA, Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study, Blood. 2015 Sep 10;126(11):1392-4. doi: 10.1182/blood-2015-05-647420.

28. Kastritis E, Kyrtsonis MC, Morel P, Gavriatopoulou M, Hatjiharissi E, Symeonidis AS, Vassou A, Repousis P, Delimpasi S, Sioni A, Michalis E, Michael M, Vervessou E, Voulgarelis M, Tsatalas C, Terpos E, Dimopoulos MA, Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy, Haematologica. 2015 Nov;100(11):e446-9. doi: 10.3324/haematol.2015.124149. Epub 2015 Aug 20.

29. Londin E, Loher P, Telonis AG, Quann K, Clark P, Jing Y, Hatzimichael E, Kirino Y, Honda S, Lally M, Ramratnam B, Comstock CE, Knudsen KE, Gomella L, Spaeth GL, Hark L, Katz LJ, Witkiewicz A, Rostami A, Jimenez SA, Hollingsworth MA, Yeh JJ, Shaw CA, McKenzie SE, Bray P, Nelson PT, Zupo S, Van Roosbroeck K, Keating MJ, Calin GA, Yeo C, Jimbo M, Cozzitorto J, Brody JR, Delgrosso K, Mattick JS, Fortina P, Rigoutsos I. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proc Natl Acad Sci U S A. 2015 Mar 10;112(10):E1106-15

30. Londin ER, Hatzimichael E, Loher P, Edelstein L, Shaw C, Delgrosso K, Fortina P, Bray PF, McKenzie SE, Rigoutsos I. The human platelet: strong transcriptome correlations among individuals associate weakly with the platelet proteome. Biol Direct. 2014 Feb 14;9:3

31. Katodritou E, Vadikolia C, Lalagianni C, Kotsopoulou M, Papageorgiou G, Kyrtsonis MC, Matsouka P, Giannakoulas N, Kyriakou D, Karras G, Anagnostopoulos N, Michali E, Briasoulis E, Hatzimichael E, Spanoudakis E, Zikos P, Tsakiridou A, Tsionos K, Anargyrou K, Symeonidis A, Maniatis A, Terpos E. “Real-world” data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. Ann Hematol. 2014 Jan;93(1):129-39

32. Kastritis E, Zagouri F, Symeonidis A, Roussou M, Sioni A, Pouli A, Delimpasi S, Katodritou E, Michalis E, Michael M, Hatzimichael E, Vassou A, Repousis P, Christophoridou A, Kartasis Z, Stefanoudaki E, Megalakaki C, Giannouli S, Kyrtsonis MC, Konstantopoulos K, Spyroupoulou-Vlachou M, Terpos E, Dimopoulos MA; Greek Myeloma Study Group, Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma, Leukemia. 2014 Oct;28(10):2075-9. doi: 10.1038/leu.2014.110. Epub 2014 Mar 18

33. Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis MC, Repousis P, Kartasis Z, Parcharidou A, Michael M, Michalis E, Gika D, Symeonidis A, Pouli A, Konstantopoulos K, Terpos E, Kastritis E, Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents, Ann Oncol. 2014 Jan;25(1):195-200. doi: 10.1093/annonc/mdt483.

34. Ximeri M, Galanopoulos A, Klaus M, Parcharidou A, Giannikou K, Psyllaki M, Symeonidis A, Pappa V, Kartasis Z, Liapi D, Hatzimichael E, Kokoris S, Korkolopoulou P, Sambani C, Pontikoglou C, Papadaki HA. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion. Haematologica 2010;95:406-414.

35. Lee S, Syed N, Taylor J, Smith P, Griffin B, Baens M, Bai M, Bourantas K, Stebbing J, Naresh K, Nelson M, Tuthill M, Bower M, Hatzimichael E, Crook T. DUSP16 is an epigenetically regulated determinant of JNK signalling in Burkitt’s lymphoma. Br J Cancer 2010;103:265-274.

36. Wang H, Lee S, Nigro CL, Lattanzio L, Merlano M, Monteverde M, Matin R, Purdie K, Mladkova N, Bergamaschi D, Harwood C, Syed N, Szlosarek P, Briasoulis E, McHugh A, Thompson A, Evans A, Leigh I, Fleming C, Inman GJ, Hatzimichael E, Proby C, Crook T. NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity. Br J Cancer 2012;106:1446-1452.

37. Lo Nigro C, Monteverde M, Lee S, Lattanzio L, Vivenza D, Comino A, Syed N, McHugh A, Wang H, Proby C, Garrone O, Merlano M, Hatzimichael E, Briasoulis E, Gojis O, Palmieri C, Jordan L, Quinlan P, Thompson A, Crook T. NT5E CpG island methylation is a favourable breast cancer biomarker. Br J Cancer 2012;107:75-83.

38. Dimopoulos MA, Kastritis E, Delimpasi S, Katodritou E, Hatzimichael E, Kyrtsonis MC, Repousis P, Tsirogianni M, Kartasis Z, Parcharidou A, Michael M, Michalis E, Tsatalas C, Stefanoudaki E, Hatjiharissi E, Gika D, Symeonidis A, Terpos E, Zervas K. Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era. Eur J Haematol 2012;89:10-15.

39. Syed N, Coley HM, Sehouli J, Koensgen D, Mustea A, Szlosarek P, McNeish I, Blagden SP, Schmid P, Lovell DP, Hatzimichael E, Crook T. Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer. Cancer Res 2011;71:3317-3327.

40. Kastritis E, Zervas K, Repoussis P, Michali E, Katodrytou E, Zomas A, Simeonidis A, Terpos E, Delimbassi S, Vassou A, Gika D, Dimopoulos MA; Greek Myeloma Study Group., Prognostication in young and old patients with Waldenström’s macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase, Clin Lymphoma Myeloma. 2009 Mar;9(1):50-2. doi: 10.3816/CLM.2009.n.012.

41. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Zervas K, Tsatalas C, Kokkinis G, Repoussis P, Symeonidis A, Delimpasi S, Katodritou E, Vervessou E, Michali E, Pouli A, Gika D, Vassou A, Terpos E, Anagnostopoulos N, Economopoulos T, Pangalis G., Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide, J Clin Oncol. 2007 Aug 1;25(22):3344-9. doi: 10.1200/JCO.2007.10.9926. Epub 2007 Jun 18.

42. Dimopoulos MA, Anagnostopoulos A, Terpos E, Repoussis P, Zomas A, Katodritou E, Kyrtsonis MC, Delibasi S, Vassou A, Pouli A, Zervas K, Anagnostopoulos N, Maniatis A; Greek Myeloma Study Group. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma, Haematologica. 2006 Feb;91(2):252-4.

43. Pentheroudakis G, Malamou-Mitsi V, Briasoulis E, Damala K, Vassou A, Vartholomatos G, Kolaitis N, Pavlidis N. The neutrophil, not the tumor: serum CA 15-3 elevation as a result of granulocyte–colony-stimulating factor-induced neutrophil MU1C overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy, Cancer. 2004 Oct 15;101(8):1767-75. doi: 10.1002/cncr.20581.

     

1. E. Tzavella, L. Gika, E. Hatzimichael, H. Milionis, E. Liberopoulos Severe thrombocytopenia in COVID-19: a case report. Journal of Atherosclerosis Prevention and Treatment, in press

2. Liontos A, Koumpis E, Barkas F, Hatzimichael E, Liamis G, Fever of unknown origin as the only manifestation of multiple myeloma. A case report. Arch Hellen Med, 38(6), November-December 2021, 795-797

3. Papakonstantinou I, Koumpis E, Fytsili E, Panteli A, Milionis H, Papoudou-Bai A, Kapsali E, Hatzimichael E, Leishmaniasis mimicking multiple myeloma. Int J Lab Hematol 2021 Jul 29. doi: 10.1111/ijlh.13667

4. Papakonstantinou I, Kosmidou M, Papathanasiou K, Koumpis E, Kapsali E, Milionis H, Vassilakopoulos TP, Papoudou-Bai A, Hatzimichael E, Paraneoplastic Intrahepatic Cholestasis in Supradiaphragmatic Classical Hodgkin Lymphoma Successfully Treated with Brentuximab Vedotin: A Case Report and Review of the Literature. In Vivo. 2021 Jul-Aug;35(4):1951-1957.

5. Koumpis E, Papathanasiou K, Papakonstantinou I, Tassi I, Serpanou A, Kapsali E, Hatzimichael E, Rifampicin-Induced Thrombocytopenia: A Case Report and Short Review of the Literature. EMJ. 2021; DOI/10.33590/emj/20-00193.

6. Voulgari PV, Kapsali E, Leishmaniasis After Multiple Sandfly Bites,J Clin Rheumatol 2021 Sep 1;27(6):e235. doi: 10.1097/

7. Papoudou-Bai A, Vassou A, Marinos L, Papathanasiou K, Kapsali E, Kanavaros P, Concurrent cutaneous localization of Langerhans cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma in a patient with a history of chronic lymphocytic leukemia/small lymphocytic lymphoma, J Cutan Pathol. 2020 Feb;47(2):161-165.doi: 10.1111/cup.13571. Epub 2019 Aug 23

8. Papoudou-Bai A, Marinos L, Vassou A, Kapsali E, Kanavaros P, CD5-Positive Primary Cutaneous Diffuse Large B-Cell Lymphoma-Leg Type, Case Rep Dermatol Med. 2019 Jan 16;2019:3730915. doi: 10.1155/2019/3730915. eCollection 2019

9. Papoudou-Bai A, Marinos L, Papathanasiou K, Kanavaros P, Kapsali E, Simultaneous Presence of Follicular Lymphoma, Diffuse Large B-cell Lymphoma, and Hodgkin-like Lymphoma, Turk J Haematol. 2018 Nov 13;35(4):308-309. doi: 10.4274/tjh.2018.0183. Epub 2018 Aug 1.

10. Gaitanis G, Gougopoulou D, Kapsali E, Bassukas ID, Sustained Regression of Hydroxycarbamide Induced Actinic Keratoses after Switching to Anagrelide, Case Rep Dermatol Med. 2018 Mar 27;2018:2874012. doi: 10.1155/2018/2874012. eCollection 2018

11. Hatzimichael E, Papathanasiou K, Zerdes I, Flindris S, Papoudou-Bai A, Kapsali E., Plasmablastic Lymphoma with Coexistence of Chronic Lymphocytic Leukemia in an Immunocompetent Patient: A Case Report and Mini-Review, Case Rep Hematol. 2017;2017:2861596. doi: 10.1155/2017/2861596. Epub 2017 Nov 20.

12. Bourantas LK, Pappas G, Kapsali E, Gougopoulou D, Papamichail D, Bourantas KL, Brucellosis-induced autoimmune hemolytic anemia treated with rituximab, Ann Pharmacother. 2010 Oct;44(10):1677-80. doi: 10.1345/aph.1P249. Epub 2010 Sep 7.

13. Hatzimichael E, Benetatos L, Stebbing J, Kapsali E, Panayiotopoulou S, Bourantas KL. Spontaneous splenic haematoma in a multiple myeloma patient receiving pegfilgrastim support, Clin Lab Haematol. 2006 Dec;28(6):416-8. doi: 10.1111/j.1365-2257.2006.00819.x.

14. Tsiara SN, Chaidos A, Gouva M, Christou L, Panteli K, Kapsali E, Bourantas KL. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone, J Exp Clin Cancer Res. 2004 Mar;23(1):47-52.

15. Vartholomatos G, Kapsali E, Dokou E, Bourantas KL., Lack of HLA-DR expression in a patient with B-chronic lymphocytic leukemia, J Exp Clin Cancer Res. 2001 Jun;20(2):305-6.

16. Kapsali E, Tsiara S, Christou L, Panteli A, Bourantas KL. Two siblings with chronic myelogenous leukemia, J Exp Clin Cancer Res. 2000 Dec;19(4):541-3.

17. Tsiara S, Economou G, Panteli A, Isaakidis P, Kapsali E, Bourantas KL. Coexistence of myelodysplastic syndrome and multiple myeloma, J Exp Clin Cancer Res. 1999 Dec;18(4):565-6.

18. Mavroeidis L, Vassou A, Zarkavelis G, Papadaki A, Mouzaki I, Ntellas P, Gkoura S, Gazouli I, Pentheroudakis G., Acquired Hemophilia in an Elderly Patient with Carcinoma of the Ampulla of Vater, Case Rep Oncol. 2020 Jan 13;13(1):1-6. doi: 10.1159/000504338. eCollection Jan-Apr 2020.

19. Boussios S, Zerdes I, Vassou A, Bareta E, Seraj E, Papoudou-Bai A, Pavlidis N, Batistatou A, Pentheroudakis G, Extranodal diffuse large B-cell lymphomas: A retrospective case series and review of the literature, Hematol Rep. 2018 Apr 3;10(1):7070.doi: 10.4081/hr.2018.7070. eCollection 2018 Mar 2

20. Kastrisiou M, Kostadima FL, Kefas A, Zarkavelis G, Kapodistrias N, Ntouvelis E, Petrakis D, Papadaki A, Vassou A, Pentheroudakis G., Nivolumab-induced hypothyroidism and selective pituitary insufficiency in a patient with lung adenocarcinoma: a case report and review of the literature, ESMO Open. 2017 Oct 5;2(4):e000217. doi: 10.1136/esmoopen-2017-000217. eCollection 2017.

21. Papoudou-Bai A, Vassou A, Vartholomatos G, Briasoulis E, Kanavaros P,  Composite hairy cell leukemia and chronic lymphocytic leukemia, J BUON. Jul-Aug 2016;21(4):1027-1029.

22. Hatzimichael E, Lagos K, Vassou A, Gougopoulou D, Papoudou-Bai A, Briasoulis E, Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatment, Mol Clin Oncol. 2016 Jul;5(1):23-26. doi: 10.3892/mco.2016.866. Epub 2016 Apr 20

23. Katsanos KH, Vagias I, Tsianos VE, Vassou A, Tsianos EV., Chronic myelogenous leukemia in ulcerative colitis, Ann Gastroenterol. 2011;24(1):64.

24. Voulgaris E, Pentheroudakis G, Vassou A, Pavlidis N., Disseminated intravascular coagulation (DIC) and non-small cell lung cancer (NSCLC): report of a case and review of the literature, Lung Cancer. 2009 May;64(2):247-9. doi: 10.1016/j.lungcan.2008.10.027. Epub 2008 Dec 12.

25. Vassou A, Bai M, Benetatos L, Tsili A, Bourantas K., Large B-cell transformation of chronic lymphocytic leukemia presenting as a penile mass and skin lesion, Hematol Oncol Stem Cell Ther. Jul-Sep 2008;1(3):199-200. doi: 10.1016/s1658-3876(08)50032-x.

26. Benetatos L, Alymara V, Chaidos A, Vassou A, Bourantas KL, Non-secretory multiple myeloma with involvement of the hand as initial manifestation, Leuk Lymphoma. 2006 Aug;47(8):1677-9. doi: 10.1080/10428190600612420.

27. Benetatos L, Hatzimichael E, Vassou A, Bourantas KL. Cryptococcus lung infection complicating fludarabine treatment in a chronic lymphocytic leukemia patient, Leuk Res. 2007 Jan;31(1):119-20. doi: 10.1016/j.leukres.2006.03.008. Epub 2006 Apr 18.

28. Vassou A, Alymara V, Agelis E, Stefanaki S, Bourantas KL. Multifocal extramedullary plasmacytoma with paraproteinemia, pleural involvement and retroperitoneal lymphadenopathy: an uncommon pattern of relapse of solitary osseous plasmacytoma. Ann Hematol. 2006 May;85(5):335-6. doi: 10.1007/s00277-006-0086-4. Epub 2006 Feb 22.

29. Kalambokis G, Vassou A, Bourantas K, Tsianos EV, Imipenem-cilastatin induced pure white cell aplasia Scand J Infect Dis. 2005;37(8):619-620. doi: 10.1080/00365540510040205.

30. Pomoni A, Aggeli I, Loutsi E, Hatzimichael E, Chaliasos N, Makis A. Cyanosis Due to Methemoglobinemia as the Presenting Sign of Glucose-6-Phosphate Dehydrogenase Deficiency in a Child: Diagnostic and Clinical Implications. J Pediatr Hematol Oncol. 2020 Oct 7. doi: 10.1097/

31. Makis A, Georgiou I, Traeger-Synodinos J, Storino MR, Giuliano M, Andolfo I, Hatzimichael E, Chaliasos N, Giapros V, Izzo P, Iolascon A, Grosso M. A Novel εγδβ-Thalassemia Deletion Associated with Severe Anemia at Birth and a β-Thalassemia Intermedia Phenotype Later in Life in Three Generations of a Greek Family. Hemoglobin. 2019 Dec 12:1-4.

32. Tzavella E, Hatzimichael E, Kostara C, Bairaktari E, Elisaf M, Tsimihodimos V. Sitosterolemia: A multifaceted metabolic disorder with important clinical consequences. J Clin Lipidol. Jul-Aug;11(4):1095-1100. doi: 10.1016/j.jacl.2017.04.116. Epub 2017 Apr 30

33. Hatzimichael E, Briasoulis E. Megaloblastic anemia presenting with skin hyperpigmentation. International Journal of Hematology, 2016; 103(5):479-80

34. Papoudou-Bai A, Hatzimichael E, Kyriazopoulou L, Briasoulis E, Kanavaros P. Rare variants in the spectrum of human herpesvirus 8/Epstein-Barr virus-copositive lymphoproliferations. Hum Pathol. 2015 Oct;46(10):1566-71.

35. Bourantas KL, Hatzimichael E, Tsiara, S. Elisaf, M. Konstantinidou, E. Xefteri, E. A patient with Down’s syndrome and acute lymphoblastic leukemia who relapsed 20 years after first remission. Haema 2000;3.

36. Christou L, Hatzimichael E, Sotsiou-Candila F, Siamopoulos K, Bourantas KL. A patient with multiple myeloma, amyloidosis and light-chain deposition disease in kidneys with a long survival. Acta Haematol 1999;101:202-205.

1. Koumpis E, Tassi I, Malea T, Papathanasiou K, Papakonstantinou I, Serpanou A, Tsolas E, Kapsali E, Vassilakopoulos TP, Papoudou-Bai A, Hatzimichael E, CD56 expression in multiple myeloma: Correlation with poor prognostic markers but no effect on outcome. Pathol Res Pract. 2021 Jul 28;225:153567
2. Bourantas KL, Hatzimichael EC, Makis AC, Chaidos A, Kapsali ED, Tsiara S, Mavridis A. Serum beta-2-microglobulin, TNF-alpha and interleukins in myeloproliferative disorders, Eur J Haematol. 1999 Jul;63(1):19-25. doi: 10.1111/j.1600-0609.1999.tb01845.x.
3. Papadopoulou V, Kontandreopoulou E, Panayiotidis P, Roumelioti M, Angelopoulou M, Kyriazopoulou L, Diamantopoulos PT, Vaiopoulos G, Variami E, Kotsianidis I, Athina Viniou N. Expression, prognostic significance and mutational analysis of protein tyrosine phosphatase SHP-1 in chronic myeloid leukemia, Leuk Lymphoma. 2016 May;57(5):1182-8. doi: 10.3109/10428194.2015.1090573. Epub 2015 Dec 23.,
4. Lambri E, Sainis I, Kounnis I, Mistelou A, Ioachim E, Hatzimichael E, Galani V, Briasoulis E. SLCO1B3 screening in colorectal cancer patients using High-Resolution Melting Analysis method and immunohistochemistry. Tumour Biol. 2017 Mar;39(3)
5. Papoudou-Bai A, Hatzimichael E, Barbouti A, Kanavaros P.  Expression patterns of the activator protein-1 (AP-1) family members in lymphoid neoplasms. Clin Exp Med. 2017Aug;17(3):291-304.
6. Londin E, Loher P, Telonis AG, Quann K, Clark P, Jing Y, Hatzimichael E, Kirino Y, Honda S, Lally M, Ramratnam B, Comstock CE, Knudsen KE, Gomella L, Spaeth GL, Hark L, Katz LJ, Witkiewicz A, Rostami A, Jimenez SA, Hollingsworth MA, Yeh JJ, Shaw CA, McKenzie SE, Bray P, Nelson PT, Zupo S, Van Roosbroeck K, Keating MJ, Calin GA, Yeo C, Jimbo M, Cozzitorto J, Brody JR, Delgrosso K, Mattick JS, Fortina P, Rigoutsos I. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proc Natl Acad Sci U S A. 2015 Mar 10;112(10):E1106-15
7. Primikyri A, Chatziathanasiadou MV, Karali E, Kostaras E, Mantzaris MD, Hatzimichael E, Shin JS, Chi SW, Briasoulis E, Kolettas E, Gerothanassis IP, Tzakos AG. Direct binding of bcl-2 family proteins by quercetin triggers its pro-apoptotic activity. ACS Chem Biol. 2014 Dec 19;9(12):2737-41.
8. Londin ER, Hatzimichael E, Loher P, Edelstein L, Shaw C, Delgrosso K, Fortina P, Bray PF, McKenzie SE, Rigoutsos I. The human platelet: strong transcriptome correlations among individuals associate weakly with the platelet proteome. Biol Direct. 2014 Feb 14;9:3
9. Makis A, Challa A, Hatzimichael E, Briasoulis E, Siamopoulou A, Chaliasos N. Adipocytokines are related to haemolytic and inflammatory biomarkers in sickle cell beta thalassaemia. Br J Haematol. 2013 Oct;163(1):142-4.
10. Hatzimichael E, Murray S, Briasoulis E. Absence of BRAF exon 15 mutations in multiple myeloma and Waldenström’s macroglobulinemia questions its validity as a therapeutic target in plasma cell neoplasias. Am J Blood Res. 2013
11. Lo Nigro C, Wang H, McHugh A, Lattanzio L, Matin R, Harwood C, Syed N, Hatzimichael E, Briasoulis E, Merlano M, Evans A, Thompson A, Leigh I, Fleming C, Inman GJ, Proby C, Crook T. Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma. J Invest Dermatol. 2013 May;133(5):1278-85
12. Syed N, Langer J, Janczar K, Singh P, Lo Nigro C, Lattanzio L, Coley HM, Hatzimichael E, Bomalaski J, Szlosarek P, Awad M, O’Neil K, Roncaroli F, Crook T. Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma. Cell Death Dis. 2013 Jan 17;4:e458
13. Hatzimichael E, Lo Nigro C, Lattanzio L, Syed N, Shah R, Dasoula A, Janczar K, Vivenza D, Monteverde M, Merlano M, Papoudou-Bai A, Bai M, Schmid P, Stebbing J, Bower M, Dyer MJ, Karran LE, ElguetaKarstegl C, Farrell PJ, Thompson A, Briasoulis E, Crook T. The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma. Br J Cancer. 2012 Oct 9;107(8):1423-32.
14. Delage B, Luong P, Maharaj L, O’Riain C, Syed N, Crook T, Hatzimichael E, Papoudou-Bai A, Mitchell TJ, Whittaker SJ, Cerio R, Gribben J, Lemoine N, Bomalaski J, Li CF, Joel S, Fitzgibbon J, Chen LT, Szlosarek PW. Promoter methylation of arginosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. Cell Death Dis 2012: 5:e342
15. Wang H, Lee S, Nigro CL, Lattanzio L, Merlano M, Monteverde M, Matin R, Purdie K, Mladkova N, Bergamaschi D, Harwood C, Syed N, Szlosarek P, Briasoulis E, McHugh A, Thompson A, Evans A, Leigh I, Fleming C, Inman GJ, Hatzimichael E, Proby C, Crook T. NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity. Br J Cancer 2012;106:1446-1452.
16. Lo Nigro C, Monteverde M, Lee S, Lattanzio L, Vivenza D, Comino A, Syed N, McHugh A, Wang H, Proby C, Garrone O, Merlano M, Hatzimichael E, Briasoulis E, Gojis O, Palmieri C, Jordan L, Quinlan P, Thompson A, Crook T. NT5E CpG island methylation is a favourable breast cancer biomarker. Br J Cancer 2012;107:75-83.
17. Hatzimichael E, Dasoula A, Kounnis V, Benetatos L, Nigro CL, Lattanzio L, Papoudou-Bai A, Dranitsaris G, Briasoulis E, Crook T. Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory disease with therapeutic implications. Leuk Lymphoma 2012.
18. Syed N, Coley HM, Sehouli J, Koensgen D, Mustea A, Szlosarek P, McNeish I, Blagden SP, Schmid P, Lovell DP, Hatzimichael E, Crook T. Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer. Cancer Res 2011;71:3317-3327.
19. Benetatos L, Dasoula A, Hatzimichael E, Syed N, Voukelatou M, Dranitsaris G, Bourantas KL, Crook T. Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions. Ann Hematol 2011;90:1037-1045.
20. Ximeri M, Galanopoulos A, Klaus M, Parcharidou A, Giannikou K, Psyllaki M, Symeonidis A, Pappa V, Kartasis Z, Liapi D, Hatzimichael E, Kokoris S, Korkolopoulou P, Sambani C, Pontikoglou C, Papadaki HA. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion. Haematologica 2010;95:406-414.
21. Makis A, Shipway D, Hatzimichael E, Galanakis E, Pshezhetskiy D, Chaliasos N, Stebbing J, Siamopoulou A. Cytokine and adhesion molecule expression evolves between the neutrophilic and lymphocytic phases of viral meningitis. J Interferon Cytokine Res 2010;30:661-665.
22. Lee S, Syed N, Taylor J, Smith P, Griffin B, Baens M, Bai M, Bourantas K, Stebbing J, Naresh K, Nelson M, Tuthill M, Bower M, Hatzimichael E, Crook T. DUSP16 is an epigenetically regulated determinant of JNK signalling in Burkitt’s lymphoma. Br J Cancer 2010;103:265-274.
23. Hatzimichael E, Dasoula A, Shah R, Syed N, Papoudou-Bai A, Coley HM, Dranitsaris G, Bourantas KL, Stebbing J, Crook T. The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia. Eur J Haematol 2010;84:47-51.
24. Hatzimichael E, Dasoula A, Benetatos L, Syed N, Dranitsaris G, Crook T, Bourantas K. Study of specific genetic and epigenetic variables in multiple myeloma. Leuk Lymphoma 2010;51:2270-2274.
25. Chaliasos N, Challa A, Hatzimichael E, Koutsouka F, Bourantas DK, Vlahos AP, Siamopoulou A, Bourantas KL, Makis A. Serum adipocytokine and vascular inflammation marker levels in Beta-thalassaemia major patients. Acta Haematol 2010;124:191-196.
26. Benetatos L, Hatzimichael E, Dasoula A, Dranitsaris G, Tsiara S, Syrrou M, Georgiou I, Bourantas KL. CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes. Leuk Res 2010;34:148-153
27. Hatzimichael E, Dranitsaris G, Dasoula A, Benetatos L, Stebbing J, Crook T, Bourantas KL. Von Hippel-Lindau methylation status in patients with multiple myeloma: a potential predictive factor for the development of bone disease. Clin Lymphoma Myeloma 2009;9:239-242.
28. Hatzimichael E, Benetatos L, Dasoula A, Dranitsaris G, Tsiara S, Georgiou I, Syrrou M, Stebbing J, Coley HM, Crook T, Bourantas KL. Absence of methylation-dependent transcriptional silencing in TP73 irrespective of the methylation status of the CDKN2A CpG island in plasma cell neoplasia. Leuk Res 2009;33:1272-1275.
29. Hatzimichael E, Dasoula A, Benetatos L, Makis A, Stebbing J, Crook T, Syrrou M, Bourantas KL. The absence of CDKN1C (p57KIP2) promoter methylation in myeloid malignancies also characterizes plasma cell neoplasms. Br J Haematol 2008;141:557-558.
30. Benetatos L, Dasoula A, Syed N, Hatzimichael E, Crook T, Bourantas KL. Methylation analysis of the von Hippel-Lindau gene in acute myeloid leukaemia and myelodysplastic syndromes. Leukemia 2008;22:1293-1295
31. Benetatos L, Dasoula A, Hatzimichael E, Georgiou I, Syrrou M, Bourantas KL. Promoter hypermethylation of the MEG3 (DLK1/MEG3) imprinted gene in multiple myeloma. Clin Lymphoma Myeloma 2008;8:171-175.
32. Panteli K, Bai M, Hatzimichael E, Zagorianakou N, Agnantis NJ, Bourantas K. Serum levels, and bone marrow immunohistochemical expression of, vascular endothelial growth factor in patients with chronic myeloproliferative diseases. Hematology 2007;12:481-486.
33. Makis AC, Hatzimichael E, Stebbing J, Bourantas KL. C-reactive protein and vascular cell adhesion molecule-1 as markers of severity in sickle cell disease. Arch Intern Med 2006;166:366-368.
34. Sfagos C, Makis AC, Chaidos A, Hatzimichael EC, Dalamaga A, Kosma K, Bourantas KL. Serum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patients. Mult Scler 2005;11:272-275.
35. Panteli KE, Hatzimichael E, Bouranta PK, Katsaraki A, Seferiadis K, Stebbing J, Bourantas KL. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol 2005;130:709-715.
36. Makis AC, Galanakis E, Hatzimichael E, Papadopoulou ZL, Siamopoulou A, Bourantas KL. Serum levels of soluble interleukin-2 receptor alpha (sIL-2Ralpha) as a predictor of outcome in brucellosis. J Infect 2005;51:206-210.
37. Makis AC, Hatzimichael E, Kolios G, Bourantas KL. Circulating endothelin-3 levels in patients with sickle cell disease during hydroxyurea treatment. Haematologica 2004;89:360-361.
38. Voulgari PV, Hatzimichael E, Tsiara S, Tzallas C, Drosos AA, Bourantas KL. Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes. Eur J Haematol 2001;66:31-36.
39. Makis AC, Chaliasos N, Hatzimichael E, Bourantas KL. Recombinant human erythropoietin therapy in a transfusion-dependent beta-thalassemia major patient. Ann Hematol 2001;80:492-495.
40. Hatzimichael E, Christou L, Bai M, Kolios G, Kefala L, Bourantas KL. Serum levels of IL-6 and its soluble receptor (sIL-6R) in Waldenstrom’s macroglobulinemia. Eur J Haematol 2001;66:1-6.
41. Makis AC, Hatzimichael E, Mavridis A, Bourantas KL. Alpha-2-macroglobulin and interleukin-6 levels in steady-state sickle cell disease patients. Acta Haematologica 2000;104:164-168.
42. Makis AC, Hatzimichael E, Bourantas KL. The role of cytokines in sickle cell disease. Ann Hematol 2000;79:407-413.
43. Bourantas KL, Hatzimichael E, Makis AC, Kapsali E, Tsiara S, Christou L, Seferiadis K. Prolonged interferon-alpha-2b treatment of hairy cell leukemia patients. Eur J Haematol 2000;64:350-351.

1. Makis A, Voskaridou E, Papassotiriou I, Hatzimichael E. Novel therapeutic advances in β-thalassemia, Biology (Basel) 2021 Jun 18;10(6):546 

2. Papakonstantinou I, Kosmidou M, Papathanasiou K, Koumpis E, Kapsali E, Milionis H, Vassilakopoulos TP, Papoudou-Bai A, Hatzimichael E, Paraneoplastic Intrahepatic Cholestasis in Supradiaphragmatic Classical Hodgkin Lymphoma Successfully Treated with Brentuximab Vedotin: A Case Report and Review of the Literature. In Vivo. 2021 Jul-Aug;35(4):1951-1957.

3. Koumpis E, Papathanasiou K, Papakonstantinou I, Tassi I, Serpanou A, Kapsali E, Hatzimichael E, Rifampicin-Induced Thrombocytopenia: A Case Report and Short Review of the Literature. EMJ. 2021; DOI/10.33590/emj/20-00193.

4. Koumpis E, Florentin M, Hatzimichael E, Liamis G, Hyponatremia in Patients with Hematologic Diseases. J Clin Med 2020 Nov 19;9(11):3721

5. Kosmeri C, Koumpis E, Tsabouri S, Siomou E, Makis A. Hematological manifestations of SARS-CoV-2 in children, Pediatr Blood Cancer. 2020 Dec;67(12):e28745. doi: 10.1002/pbc.28745. Epub 2020 Oct 3.

6. Prieto JC, Vallejo Casas JA, Hatzimichael E, Fotopoulos A, Kiortsis DN, Sioka C. The contribution of metabolic parameters of FDG PET/CT prior and during therapy of adult patients with lymphomas. Ann Nucl Med. 2020 Oct;34(10):707-717. doi: 10.1007/s12149-020-01521-3.

7. Tsolkas G, Komninou D, Briasoulis E, Hatzimichael E, Papanikolaou NA. A Novel Therapeutic Approach in Acute Promyelocytic Leukemia with All-trans retinoic Acid and Cyclin-dependent Kinase Inhibitors. Clin Cancer Drugs 2018;5: 50-59

8. Hatzimichael E, Papathanasiou K, Zerdes I, Flindris S, Papoudou-Bai A, Kapsali E., Plasmablastic Lymphoma with Coexistence of Chronic Lymphocytic Leukemia in an Immunocompetent Patient: A Case Report and Mini-Review, Case Rep Hematol. 2017;2017:2861596. doi: 10.1155/2017/2861596. Epub 2017 Nov 20.

9. Tzavella E, Hatzimichael E, Kostara C, Bairaktari E, Elisaf M, Tsimihodimos V. Sitosterolemia: A multifaceted metabolic disorder with important clinical consequences. J Clin Lipidol. Jul-Aug;11(4):1095-1100. doi: 10.1016/j.jacl.2017.04.116. Epub 2017 Apr 30

10. Lambri E, Sainis I, Kounnis I, Mistelou A, Ioachim E, Hatzimichael E, Galani V, Briasoulis E. SLCO1B3 screening in colorectal cancer patients using High-Resolution Melting Analysis method and immunohistochemistry. Tumour Biol. 2017 Mar;39(3)

11. Biziota E, Mavroiedis L, Hatzimichael E, Pappas P. Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation. Cancer Lett 2017 Aug 1;400:243-251. doi: 10.1016/j.canlet.2016.12.018.

12. Boussios S, Zerdes I, Vassou A, Bareta E, Seraj E, Papoudou-Bai A, Pavlidis N, Batistatou A, Pentheroudakis G, Extranodal diffuse large B-cell lymphomas: A retrospective case series and review of the literature, Hematol Rep. 2018 Apr 3;10(1):7070.doi: 10.4081/hr.2018.7070. eCollection 2018 Mar 2

13. Makis A, Hatzimichael E, Papassotiriou I, Voskaridou E. 2017 Clinical trials update in new treatments of β-thalassemia. Am J Hematol 2016 Nov;91(11):1135-1145

14. Papoudou-Bai A, Hatzimichael E, Barbouti A, Kanavaros P.  Expression patterns of the activator protein-1 (AP-1) family members in lymphoid neoplasms. Clin Exp Med. 2017Aug;17(3):291-304.

15. Hatzimichael E, Lagos K, Sim VR, Briasoulis E, Crook T. Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update. EXCLI Journal 2014;13:954-976

16. Hatzimichael E, Tsolas E, Briasoulis E. Profile of pacritinib and its potential in the treatment of hematologic disorders. J Blood Med. 2014 Aug 19;5:143-52.

17. Benetatos L, Vartholomatos G, Hatzimichael E. DLK1-DIO3 imprinted cluster in induced pluripotency: landscape in the mist. Cell Mol Life Sci. 2014 Nov;71(22):4421-30.

18. Benetatos L, Hatzimichael E. Delta-Like Homologue 1 and Its Role in the Bone Marrow Niche and Hematologic Malignancies. Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):451-455.

19. Benetatos L, Vartholomatos G, Hatzimichael E. Polycomb group proteins and MYC: the cancer connection. Cell Mol Life Sci. 2014 Jan;71(2):257-69.

20. Hatzimichael E, Crook T. Cancer epigenetics: new therapies and new challenges. J Drug Deliv. 2013;2013:529312

21. Hatzimichael E, Georgiou G, Benetatos L, Briasoulis E. Gene mutations and molecularly targeted therapies in acute myeloid leukemia. Am J Blood Res. 2013;3(1):29-51

22. Froudarakis M*, Hatzimichael E*, Kyriazopoulou L, Lagos K, Pappas P, Tzakos AG, Karavasilis V, Daliani D, Papandreou C, Briasoulis E. Revisiting bleomycin from pathophysiology to safe clinical use. Crit Rev Oncol Hematol. 2013 Jul;87(1):90-100

23. Dranitsaris G, Dorward K, Hatzimichael E, Amir E Clinical trial design in biosimilar drug development. Invest New Drugs. 2013 Apr;31(2):479-87.

24. Benetatos L, Voulgaris E, Vartholomatos G, Hatzimichael E. Non-coding RNAs and EZH2 interactions in cancer: long and short tales from the transcriptome. Int J Cancer. 2013 Jul 15;133(2):267-74

25. Benetatos L, Hatzimichael E, Londin E, Vartholomatos G, Loher P, Rigoutsos I, Briasoulis E. The microRNAs within the DLK1-DIO3 genomic region: involvement in disease pathogenesis. Cell Mol Life Sci. 2013 Mar;70(5):795-814

26. Tzakos AG, Fokas D, Johannes C, Moussis V, Hatzimichael E, Briasoulis E. Targeting oncogenic protein-protein interactions by diversity oriented synthesis and combinatorial chemistry approaches. Molecules 2011;16:4408-4427.

27. Hatzimichael E, Kapsali, E. Crook, T. Tuthill, M. The role of Plerixafor in the management of Non-Hodgkin’s Lymphoma. Clin Med Rev Oncol 2011;3.

28. Hatzimichael E, Briasoulis, E. Attitudes of people, authorities and doctors towards clinical cancer research: high expectations, neglected responsibilities and minimal involvement outline a hazy picture. Can we do any better? Mediterranean Oncol J 2011;1:9-13.

29. Benetatos L, Vartholomatos G, Hatzimichael E. MEG3 imprinted gene contribution in tumorigenesis. Int J Cancer 2011;129:773-779.

30. Hatzimichael E, Tuthill, M. Hematopoietic stem cell transplantation. Stem Cells Cloning  2010:105-117.

31. Voulgaris E, Pentheroudakis G, Vassou A, Pavlidis N., Disseminated intravascular coagulation (DIC) and non-small cell lung cancer (NSCLC): report of a case and review of the literature, Lung Cancer. 2009 May;64(2):247-9. doi: 10.1016/j.lungcan.2008.10.027. Epub 2008 Dec 12.

32. Benetatos L, Alymara V, Vassou A, Bourantas KL, Malignancies in beta-thalassemia patients: a single-center experience and a concise review of the literature, Int J Lab Hematol. 2008 Apr;30(2):167-72. doi: 10.1111/j.1751-553X.2007.00929.x

33. Makis AC, Hatzimichael E, Stebbing J. The genomics of new drugs in sickle cell disease. Pharmacogenomics 2006;7:909-917.

34. akis AC, Hatzimichael E, Bourantas KL. The role of cytokines in sickle cell disease. Ann Hematol 2000;79:407-413.